| 表皮生长因子受体突变:gefitinib和erlotinib治疗非小细胞肺癌的靶点研究进展 |
| |
| 引用本文： | 周冬辰,李龙芸. 表皮生长因子受体突变:gefitinib和erlotinib治疗非小细胞肺癌的靶点研究进展[J]. 癌症进展, 2006, 4(6): 540-544 |
| |
| 作者姓名： | 周冬辰 李龙芸 |
| |
| 作者单位： | 中国医学科学院,中国协和医科大学,协和医院呼吸科,北京,100730;中国医学科学院,中国协和医科大学,协和医院呼吸科,北京,100730 |
| |
| 摘 要： | Gefitinib和erlotinib是表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)类药物,是目前治疗非小细胞肺癌(NSCLC)的热点,已在多个临床试验中证实,东亚人群、女性、无吸烟史和腺癌患者有效,进一步的研究揭示癌症病人EGFR酪氨酸激酶区突变与对EGFR-TKI的敏感性密切相关。这些突变包括框架缺失、点突变等多种类型。本文综述了EGFR突变的研究现状和进展。
|
| 关 键 词： | 表皮生长因子受体 突变 非小细胞肺癌 |
Epidermal growth factor receptor mutation: The target of gefitinib and erlotinib to non- small cell lung cancer |
| |
| Zhou Dongchen,Li Longyun. Epidermal growth factor receptor mutation: The target of gefitinib and erlotinib to non- small cell lung cancer[J]. Oncology Progress, 2006, 4(6): 540-544 |
| |
| Authors: | Zhou Dongchen Li Longyun |
| |
| Abstract: | Gefitinib and erlotinib are epidermal growth factor receptor tyrosine kinase inhibitors,which are the hot points of the treatment of non-small cell lung cancer.Several clinical trials have confirmed that they are effective to East Asian,female,never-smoking and adenocarcinoma.It is found that the EGFR mutations such as in-frame deletion and point mutation are correlated with clinical response to gefitinib and erlotinib.This summary is on the research of EGFR mutations. |
| |
| Keywords: | epidermal growth factor receptor mutation non-small cell lung cancer |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
